We and others have reported that CALR mutations are associated with distinct clinical characteristics including higher platelet counts, lower leukocyte counts and hemoglobin levels, and a lower thrombosis risk when compared to JAK2-mutated ET patients [7–11]. The gene discussed is CALR; the disease is essential thrombocythemia.